LOGIN  |  REGISTER
Terns Pharmaceuticals

KindlyMD Announces Third Quarter 2024 Financial Results

November 13, 2024 | Last Trade: US$1.05 0.06 -5.41
  • Q3 Reimbursements from insurance payors totaled $106,567 an increase of 16.4% sequentially
  • KindlyMD now provides more than 90% in-network insurance coverage in Utah

SALT LAKE CITY, UT / ACCESSWIRE / November 13, 2024 / KindlyMD ("KindlyMD" or the "Company") (NASDAQ:KDLY), a patient-first healthcare and healthcare data company redefining value-based care and patient-centered medical services, today announced its financial results for the third quarter ended September 30, 2024.

"We are pleased with the progress made during the third quarter to expand our credentialing and increase insurance visits, resulting in a 16.4% growth sequentially. This greatly improves the accessibility of our services, making them available to a broader patient base and allowing financial flexibility for our patients to visit more often," Tim Pickett, PA-C, KindlyMD Founder and CEO, stated. "Our strategic focus on expanding capacity and network has proven our model can achieve in-network status with the largest payers. We can use this status to help grow the number of lives we treat in Utah and beyond. We have also begun to develop enterprise-level data analytics and are excited to drive more personalized and effective care in the fight to improve health outcomes faster and at lower patient cost. We now also have the ability to aggregate and analyze disjointed data from many sources, uncovering drug usage trends, product effectiveness, patient risk factors, and opportunities to enhance therapies."

Operational Highlights:

  • Achieved above 90% statewide insurance coverage in Utah with the addition of the largest health insurer in the United States, United Healthcare Insurance.

  • Introduced $500,000 share repurchase program to enhance shareholder value.

  • Recognized as one of the winners of the Healthcare AI Impact Award 2024.

  • Appointed Jeremy Joyal as Medical Director & Nancy Pratt as Behavioral Health Program Director.

Financial Highlights for the Quarterly Period Ended September 30, 2024

The Company earned $106,567 in reimbursements from insurance payers during the three months ended September 30, 2024, representing a 16.4% increase compared to the $91,553 earned during the three months ended June 30, 2024. The Company earned $232,892 in reimbursements from insurance payers during the nine months ended September 30, 2024, and $0 during the three and nine months ended September 30, 2023.

Revenues decreased by $221,401, or 25.5%, to $647,867 for the three months ended September 30, 2024, from $869,268 for the three months ended September 30, 2023. The decrease in revenues is primarily attributed to a decrease in cash-pay patient care services as KindlyMD continues to shift toward insurance billing with commercial and governmental payers including Medicare, Medicaid, Select Health, Blue Cross Blue Shield, Cigna, and other commercial payers compared to the prior period.

During the quarter, the Company generated revenue from service affiliate agreements for the first time. Service affiliate agreement earnings for the period were $22,432.

Operating expenses increased by $316,820, or 22.9%, to $1,697,685 for the three months ended September 30, 2024, from $1,380,865 for the three months ended September 30, 2023. The increase in operating expenses is primarily attributable to an increase in general and administrative expenses, salaries and wages, and cost of revenues.

Net loss was $1,014,147 for the three months ended September 30, 2024, compared to a net loss of $515,146 for the three months ended September 30, 2023. Net loss per share decreased by $0.06, or 54.5%, to $(0.17) for the three months ended September 30, 2024, compared to $(0.11) for the three months ended September 30, 2023. KindlyMD management strives to look for opportunities to optimize revenue by increasing sales, acquiring additional clinics, improving margins, and controlling ongoing operating expenses.

As of September 30, 2024, the company had cash and cash equivalents of $3,642,944 and total working capital of $3,215,466.

As of November 8, 2024, the Company had 5,977,476 common shares outstanding.

About KindlyMD

KindlyMD is a patient-first healthcare and healthcare data company redefining value-based care and patient-centered medical services. Kindly MD leverages data analysis to deliver evidence-based, personalized solutions in order to reduce opioid use, improve health outcomes faster, and provide algorithmic guidance on the use of alternative medicine in healthcare. We collect and analyze valuable data on alternative treatments as well as biopsychosocial factors to provide better health outcomes faster. This results in valuable data for patients, the company, and the company's investors as we aim to become a leading source of evidence-based assessment and treatment data in the fight for patients against the opioid epidemic and as we strive to be a leader in redefined value-based care.

KindlyMD provides a patient-focused healthcare experience that integrates traditional medical evaluation and management with mental health integration and compliant alternative medicine education and inclusion. We focus on creating personalized care plans for each individual that get people back to work and life faster, reduce opioid use, and have high patient satisfaction.

Its specialty outpatient clinical services are reimbursed by Medicare, Medicaid, and commercial insurance contracts as well as offered on a fee-for-service basis. For more information, please visit www.kindlymd.com.

Forward-Looking Statements

This press release contains certain forward-looking statements that are based upon current expectations and involve certain risks and uncertainties within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such forward-looking statements can be identified by the use of words such as "should," "may," "intends," "anticipates," "believes," "estimates," "projects," "forecasts," "expects," "plans," and "proposes." These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors, some of which are beyond our control and difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading "Risk Factors" in KindlyMD, Inc.'s Annual Report on Form 10-K for the fiscal year ended December 31, 2022. KindlyMD, Inc. does not undertake any duty to update any forward-looking statements except as may be required by law. The information which appears on our websites and our social media platforms, including, but not limited to, Instagram and Facebook, is not part of this press release.

KINDLY MD, INC.
CONDENSED BALANCE SHEETS

 

 

September 30, 2024

 

 

December 31, 2023

 

 

 

(Unaudited)

 

 

 

 

ASSETS

 

 

 

 

 

 

 

 

 

 

 

 

 

Current Assets

 

 

 

 

 

 

Cash and cash equivalents

 

$

3,642,944

 

 

$

525,500

 

Accounts receivable

 

 

45,323

 

 

 

28,001

 

Inventories, net

 

 

2,750

 

 

 

63,202

 

Prepaid expenses and other current assets

 

 

250,316

 

 

 

225

 

Total Current Assets

 

 

3,941,333

 

 

 

616,928

 

 

 

 

 

 

 

 

 

 

Property and equipment, net

 

 

183,349

 

 

 

235,292

 

Operating lease right-of-use assets

 

 

188,204

 

 

 

235,706

 

Security deposits

 

 

11,276

 

 

 

11,276

 

TOTAL ASSETS

 

$

4,324,162

 

 

$

1,099,202

 

 

 

 

 

 

 

 

 

 

LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Current Liabilities

 

 

 

 

 

 

 

 

Accounts payable and accrued expenses

 

$

431,516

 

 

$

329,810

 

Customer deposits

 

 

2,750

 

 

 

3,425

 

Current portion of operating lease liabilities

 

 

100,982

 

 

 

94,696

 

Current portion of finance lease liabilities

 

 

2,020

 

 

 

-

 

Current portion of notes payable, net

 

 

188,599

 

 

 

148,517

 

Derivative liability

 

 

-

 

 

 

238,000

 

Total Current Liabilities

 

 

725,867

 

 

 

814,448

 

 

 

 

 

 

 

 

 

 

Operating lease liabilities, net of current portion

 

 

106,114

 

 

 

164,295

 

Finance lease liabilities, net of current portion

 

 

8,126

 

 

 

 

 

Notes payable, net of current portion

 

 

-

 

 

 

228,871

 

TOTAL LIABILITIES

 

 

840,107

 

 

 

1,207,614

 

 

 

 

 

 

 

 

 

 

Stockholders' Equity (Deficit)

 

 

 

 

 

 

 

 

Preferred Stock, $0.001 par value, 10,000,000 shares authorized; none issued and outstanding as of September 30, 2024 and December 31, 2023

 

 

-

 

 

 

-

 

Common stock, $0.001 par value, 100,000,000 shares authorized; 5,977,476 and 4,617,798 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively

 

 

5,977

 

 

 

4,618

 

Additional paid-in capital

 

 

10,252,258

 

 

 

4,045,024

 

Accumulated deficit

 

 

(6,774,180

)

 

 

(4,158,054

)

TOTAL STOCKHOLDERS' EQUITY (DEFICIT)

 

 

3,484,055

 

 

 

(108,412

)

 

 

 

 

 

 

 

 

 

TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)

 

$

4,324,162

 

 

$

1,099,202

 

KINDLY MD, INC.
CONDENSED STATEMENTS OF OPERATIONS
(UNAUDITED)

 

 

For the Three Months Ended
September 30,

 

 

For the Nine Months Ended
September 30,

 

 

 

2024

 

 

2023

 

 

2024

 

 

2023

 

Revenues

 

$

647,867

 

 

$

869,268

 

 

$

2,115,953

 

 

$

3,009,151

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating Expenses

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cost of revenues

 

 

7,790

 

 

 

20,224

 

 

 

77,481

 

 

 

128,356

 

Salaries and wages

 

 

1,138,561

 

 

 

995,078

 

 

 

2,973,420

 

 

 

3,037,938

 

General and administrative

 

 

525,758

 

 

 

339,559

 

 

 

1,312,980

 

 

 

1,083,278

 

Depreciation

 

 

25,576

 

 

 

26,004

 

 

 

76,210

 

 

 

77,670

 

Total Operating Expenses

 

 

1,697,685

 

 

 

1,380,865

 

 

 

4,440,091

 

 

 

4,327,242

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

LOSS FROM OPERATIONS

 

 

(1,049,818

)

 

 

(511,597

)

 

 

(2,324,138

)

 

 

(1,318,091

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other Income (Expenses)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other income

 

 

45,330

 

 

 

9,001

 

 

 

71,198

 

 

 

46,302

 

Interest expense

 

 

(9,659

)

 

 

(12,550

)

 

 

(385,348

)

 

 

(20,744

)

Loss on extinguishment of debt

 

 

-

 

 

 

-

 

 

 

(38,889

)

 

 

-

 

Gain on change in fair value of derivative liability

 

 

-

 

 

 

-

 

 

 

61,051

 

 

 

-

 

Total Other Income (Expenses)

 

 

35,671

 

 

 

(3,549

)

 

 

(291,988

)

 

 

25,558

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

NET LOSS BEFORE INCOME TAXES

 

 

(1,014,147

)

 

 

(515,146

)

 

 

(2,616,126

)

 

 

(1,292,533

)

INCOME TAX EXPENSE

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

NET LOSS

 

$

(1,014,147

)

 

$

(515,146

)

 

$

(2,616,126

)

 

$

(1,292,533

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

LOSS PER COMMON SHARE - BASIC AND DILUTED

 

$

(0.17

)

 

$

(0.11

)

 

$

(0.50

)

 

$

(0.29

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

WEIGHTED-AVERAGE NUMBER OF SHARES OUTSTANDING - BASIC AND DILUTED

 

 

5,944,590

 

 

 

4,521,242

 

 

 

5,193,533

 

 

 

4,445,714

 

KINDLY MD, INC.
CONDENSED STATEMENTS OF CASH FLOWS
(UNAUDITED)

 

 

For the Nine Months Ended
September 30,

 

 

 

2024

 

 

2023

 

 

 

 

 

 

 

 

CASH FLOWS FROM OPERATING ACTIVITIES

 

 

 

 

 

 

Net loss

 

$

(2,616,126

)

 

$

(1,292,533

)

Adjustments to reconcile net loss to net cash used in operating activities:

 

 

 

 

 

 

 

 

Stock-based compensation

 

 

132,994

 

 

 

719,169

 

Depreciation expense

 

 

76,210

 

 

 

77,670

 

Loss on extinguishment of debt

 

 

38,889

 

 

 

-

 

Gain on change in fair value of derivative liability

 

 

(61,051

)

 

 

-

 

Amortization of debt discounts

 

 

367,046

 

 

 

1,912

 

Amortization of right-of-use assets

 

 

75,226

 

 

 

52,415

 

Changes in operating assets and liabilities:

 

 

 

 

 

 

 

 

Accounts receivable

 

 

(17,322

)

 

 

4,161

 

Inventories

 

 

60,452

 

 

 

(47,131

)

Prepaid expenses and other current assets

 

 

(250,091

)

 

 

33,398

 

Security deposits

 

 

-

 

 

 

3,229

 

Accounts payable and accrued expenses

 

 

101,706

 

 

 

262,667

 

Customer deposits

 

 

(675

)

 

 

(2,050

)

Operating lease liabilities

 

 

(79,619

)

 

 

(53,713

)

Net cash used in operating activities

 

 

(2,172,361

)

 

 

(240,806

)

 

 

 

 

 

 

 

 

 

CASH FLOWS FROM INVESTING ACTIVITIES

 

 

 

 

 

 

 

 

Purchases of property and equipment

 

 

(13,291

)

 

 

(14,420

)

Net cash used in investing activities

 

 

(13,291

)

 

 

(14,420

)

 

 

 

 

 

 

 

 

 

CASH FLOWS FROM FINANCING ACTIVITIES

 

 

 

 

 

 

 

 

Net proceeds from issuance of notes payable

 

 

45,000

 

 

 

-

 

Net proceeds from issuance of related party note payable

 

 

-

 

 

 

250,373

 

Net proceeds from issuance of common shares and warrants in connection with a public offering

 

 

5,860,650

 

 

 

-

 

Repayments of related party note payable

 

 

-

 

 

 

(30,820

)

Repayments of notes payable

 

 

(601,724

)

 

 

-

 

Repayments of finance lease liabilities

 

 

(830

)

 

 

-

 

Net cash provided by financing activities

 

 

5,303,096

 

 

 

219,553

 

 

 

 

 

 

 

 

 

 

NET CHANGE IN CASH AND CASH EQUIVALENTS

 

 

3,117,444

 

 

 

(35,673

)

 

 

 

 

 

 

 

 

 

CASH AND CASH EQUIVALENTS

 

 

 

 

 

 

 

 

Beginning of the period

 

 

525,500

 

 

 

186,918

 

End of the period

 

$

3,642,944

 

 

$

151,245

 

 

 

 

 

 

 

 

 

 

SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION

 

 

 

 

 

 

 

 

Cash paid for interest

 

$

19,177

 

 

$

16,133

 

Cash paid for income taxes

 

$

-

 

 

$

-

 

 

 

 

 

 

 

 

 

 

NON-CASH INVESTING AND FINANCING ACTIVITIES

 

 

 

 

 

 

 

 

Debt discounts on notes payable

 

$

10,556

 

 

$

-

 

Debt discount on related party note payable

 

$

-

 

 

$

16,627

 

Fair value of derivative liability recognized upon issuance of notes payable

 

$

38,000

 

 

$

-

 

Extinguishment of derivative liability upon settlement of notes payable

 

$

214,949

 

 

$

-

 

Finance purchases of property and equipment

 

$

10,976

 

 

$

-

 

Operating lease right-of-use asset and liability measurement

 

$

27,724

 

 

$

-

 

Contact Information
Valter Pinto
Managing Director, KCSA
This email address is being protected from spambots. You need JavaScript enabled to view it.
(212) 896-1254

Assertio

Stock Quote

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB